Biblio Discovery — Demo Discovery Service

6 results for "Lisa Pipperger"

Showing 1–6 · 0.50 seconds · RSS

  1. Journal Article Full text

    Characterization of the Anti-Viral and Vaccine-Specific CD8+ T Cell Composition upon Treatment with the Cancer Vaccine VSV-GP

    Tamara Hofer; Lisa Pipperger; Sarah Danklmaier et al.

    Vaccines, Vol. 12 No. 8 · 2024 · English · DOAJ Scopus

    Numerous factors influence the magnitude and effector phenotype of vaccine-induced CD8+ T cells, thereby potentially impacting treatment efficacy. Here, we investigate the effect of vaccination dose, route of immunization, presence of a target antigen-expressing tumor, and heterologous prime-boost…

  2. Journal Article

    Prediction and validation of murine MHC class I epitopes of the recombinant virus VSV-GP

    Saskia V. Vijver; Sarah Danklmaier; Lisa Pipperger et al.

    Frontiers in Immunology, Vol. 13 · 2023 · English · DOAJ Scopus

    Oncolytic viruses are currently tested as a novel platform for cancer therapy. These viruses preferentially replicate in and kill malignant cells. Due to their microbial origin, treatment with oncolytic viruses naturally results in anti-viral responses and general immune activation. Consequently…

  3. Journal Article

    Differential infection of murine and human dendritic cell subsets by oncolytic vesicular stomatitis virus variants

    Lisa Pipperger; Lydia Riepler; Janine Kimpel et al.

    OncoImmunology, Vol. 10 No. 1 · 2021 · English · DOAJ Scopus

    Oncolytic viruses (OVs) can eradicate tumor cells and elicit antitumor immunity. VSV-GP, a chimeric vesicular stomatitis virus (VSV) with the glycoprotein (GP) of the lymphocytic choriomeningitis virus, is a promising new OV candidate. However, the interaction of VSV-GP with host immune cells is…

  4. Journal Article

    Newly identified oncolytic VSV-GP-specific CD8+ T cell epitopes for monitoring of anti-viral immune responses in the BALB/c mouse model

    Sarah Danklmaier; Saskia V. Vijver; Lisa Pipperger et al.

    Molecular Therapy: Oncology, Vol. 33 No. 4 · 2025 · English · DOAJ Scopus

    The vesicular stomatitis virus variant VSV-GP is an oncolytic virus (OV) platform extensively studied in preclinical settings, which recently entered clinical trial testing. For oncolytic virotherapy, innate and adaptive immune system activation are considered major contributors. However, upon OV…

  5. Journal Article

    Immune transcriptomes of highly exposed SARS-CoV-2 asymptomatic seropositive versus seronegative individuals from the Ischgl community

    Hye Kyung Lee; Ludwig Knabl; Lisa Pipperger et al.

    Scientific Reports, Vol. 11 No. 1 · 2021 · English · DOAJ Scopus

    Abstract SARS-CoV-2 infection ranges from asymptomatic to severe with lingering symptomatology in some. This prompted investigation of whether or not asymptomatic disease results in measurable immune activation post-infection. Immune activation following asymptomatic SARS-CoV-2 infection was…

  6. Journal Article

    Persistence of immunity to SARS-CoV-2 over time in the ski resort Ischgl

    Wegene Borena; Zoltán Bánki; Katie Bates et al.

    EBioMedicine, Vol. 70 · 2021 · English · DOAJ Scopus

    Background In early March 2020, a SARS-CoV-2 outbreak in the ski resort Ischgl in Austria triggered the spread of SARS-CoV-2 throughout Austria and Northern Europe. In a previous study, we found that the seroprevalence in the adult population of Ischgl had reached 45% by the end of April…